One injection that could halt and potentially reverse a fatal disease
In the summer of 2021, a biotechnology company named Intellia Therapeutics crossed a threshold that medicine had long approached but never reached: the first clinical evidence that CRISPR gene-editing machinery, delivered through a vein, could rewrite the human genome from within. The therapy, NTLA-2001, targets a rare but fatal disease called ATTR amyloidosis, in which a faulty gene slowly fills the body's nerves and heart with toxic protein. Where previous treatments asked patients to manage their illness for a lifetime, this single injection asked a more ancient question — whether the source of suffering could simply be switched off.
- ATTR amyloidosis kills slowly and without mercy, dismantling nerves and hardening hearts in tens of thousands of patients who currently have no path to a cure — only a lifetime of medication that slows, but never stops, the disease.
- For the first time in human history, a CRISPR therapy was delivered intravenously, sending molecular scissors through the bloodstream in lipid nanoparticles to cut out the faulty gene directly inside liver cells.
- The Phase 1 trial's interim data, presented at a major neurology conference, put the entire premise of in vivo gene editing on trial — safety failures, immune reactions, or off-target cuts could have ended the program entirely.
- Early results suggested the approach was sound, with Intellia moving swiftly to identify optimal doses and expand testing to patients suffering the heart variant of the disease.
- With pivotal trials on the horizon and a global patient population estimated between 250,000 and 550,000, the therapy's trajectory points toward a regulatory reckoning that could redefine what it means to treat a genetic disease.
In June 2021, Intellia Therapeutics announced something medicine had never before demonstrated in a living human: a gene-editing therapy delivered intravenously, designed to permanently silence the gene behind a rare and fatal disease. The drug, NTLA-2001, targets ATTR amyloidosis — a condition in which a mutated gene causes the liver to produce misfolded proteins that accumulate in nerve and heart tissue, progressively destroying both.
What made the announcement extraordinary was not just the disease it targeted, but how the therapy reached it. Rather than editing cells outside the body and returning them to the patient — the method used in earlier CRISPR therapies — NTLA-2001 travels through the bloodstream inside lipid nanoparticles, tiny fat-encased vessels carrying the CRISPR editing machinery directly to liver cells. Once there, a guide RNA directs the Cas9 protein to the precise location on the genome, and the faulty gene is cut out entirely. The liver stops producing the toxic protein. In theory, one dose could be curative.
The Phase 1 trial enrolled up to 38 patients with the nerve-damage form of hereditary ATTR, each receiving a single intravenous dose. Interim results were presented at the Peripheral Nerve Society's annual meeting by Dr. Julian Gillmore of the National Amyloidosis Centre in London. The stakes were high: immune reactions, off-target editing, or liver toxicity could have derailed the entire program.
ATTR amyloidosis affects an estimated 50,000 people with the hereditary mutation and up to 500,000 more with the age-related wild-type form. Current treatments slow the disease but cannot stop it, and patients must take them for life. Intellia's therapy, developed in partnership with Regeneron Pharmaceuticals and built on Nobel Prize-winning CRISPR technology, offered a different proposition entirely.
With the Phase 1 data in hand, Intellia moved quickly — planning dose optimization, expansion to cardiomyopathy patients, and rapid advancement toward the pivotal trials required for regulatory approval. What the June presentation began to answer was whether the promise of rewriting the genome to cure disease had finally, for the first time, become something real.
On a June morning in 2021, Intellia Therapeutics announced something that had never been done before in a human body: a gene-editing therapy delivered through a vein, designed to permanently disable the gene responsible for a rare, fatal disease. The drug is called NTLA-2001. It targets transthyretin amyloidosis—ATTR—a condition in which a mutated gene causes the liver to produce misfolded proteins that accumulate in nerve and heart tissue, progressively destroying them.
The announcement came with interim data from the first phase of human testing. Intellia's lead scientist, John Leonard, framed it as a watershed moment: a single injection that could halt and potentially reverse a disease that currently requires patients to take medication for life. The therapy works by using CRISPR technology—a molecular scissors that can cut DNA—to knock out the faulty gene entirely. Once edited, the liver stops making the toxic protein. In theory, one dose could be curative.
What makes NTLA-2001 genuinely novel is how it reaches its target. Previous CRISPR therapies edited genes in cells removed from the body, then returned those corrected cells to patients. NTLA-2001 travels through the bloodstream in lipid nanoparticles—tiny fat bubbles—that ferry the editing machinery directly to liver cells. The particles carry two components: a guide RNA that directs the scissors to the right spot on the genome, and messenger RNA that tells cells how to make the Cas9 protein that does the cutting. It is, in essence, a software update delivered intravenously.
The Phase 1 trial enrolled up to 38 patients between ages 18 and 80, all living with hereditary ATTR amyloidosis with polyneuropathy—the nerve-damage variant of the disease. Patients received a single intravenous dose. The trial's primary goal was to measure safety, tolerability, and whether the drug actually worked at the molecular level. The interim data, presented on June 26 at the Peripheral Nerve Society's annual meeting by Dr. Julian Gillmore of the National Amyloidosis Centre in London, would show whether the approach was sound.
ATTR itself is rare but devastating. An estimated 50,000 people worldwide carry the hereditary mutation. Another 200,000 to 500,000 have the wild-type form, in which non-mutated TTR protein still accumulates with age. The disease manifests in two main ways: as polyneuropathy, where protein deposits damage peripheral nerves, causing progressive weakness and numbness; or as cardiomyopathy, where deposits stiffen the heart muscle and lead to heart failure. Both are progressive. Both are fatal without intervention. Current treatments—tafamidis, diflunisal, and others—slow progression but do not stop it, and patients must take them indefinitely.
Intellia's strategy after the Phase 1 readout was to move quickly. Once the company identified an optimal dose from the dose-escalation portion of the trial, it planned to expand testing to a broader population, including patients with the cardiomyopathy form. The company signaled its intention to move rapidly into pivotal trials—the larger, more rigorous studies required for regulatory approval. Intellia was also pursuing regulatory authorizations in multiple countries, expanding the trial's reach beyond its initial sites.
The drug is being developed in partnership with Regeneron Pharmaceuticals, which shares development and commercialization rights. The intellectual property foundation rests on CRISPR/Cas9 technology, which won the Nobel Prize in Chemistry in 2020. Intellia's particular innovation was the delivery system—the non-viral platform using lipid nanoparticles to reach the liver without triggering immune rejection. Preclinical data had shown deep and sustained reduction in transthyretin levels after the gene was knocked out, suggesting the effect could be durable.
What hung in the balance was whether those preclinical results would translate to humans. Safety was paramount. Immune reactions, off-target editing, liver toxicity—any of these could derail the program. But if the interim data held, NTLA-2001 could represent a genuine inflection point: the first systemic, in vivo CRISPR therapy to reach human testing, and potentially the first to offer a functional cure for a genetic disease. The presentation on June 26 would begin to answer whether that promise was real.
Notable Quotes
By knocking out the disease-causing gene, NTLA-2001 is designed to halt progression and potentially reverse the disease with a single dose, offering meaningful improvement over standard care, which requires chronic, lifelong administration.— John Leonard, Intellia President and CEO
The Hearth Conversation Another angle on the story
Why does it matter that this therapy is delivered systemically, through the bloodstream, rather than the way earlier CRISPR treatments worked?
Because it changes what's possible. Before, you had to remove cells from a patient's body, edit them in a lab, and put them back. That works for blood disorders and some cancers, but it doesn't work for organs you can't easily extract. With NTLA-2001, the editing machinery travels to where the disease is—the liver—without surgery. You inject it and it finds its target.
The source material says this is a "single-dose" therapy. How is that different from what patients are doing now?
Current ATTR drugs are like managing diabetes with insulin. You take them every day, forever. They slow the disease but don't stop it. NTLA-2001, if it works, is more like a vaccine—one shot that permanently disables the gene causing the problem. The liver stops making the toxic protein. In theory, you're done.
What's the actual disease like for someone living with it?
It depends on the form. With polyneuropathy, you lose sensation and strength in your limbs, progressively. Your hands and feet go numb. You can't walk. With cardiomyopathy, your heart stiffens and fails. Both are fatal. Both are rare enough that many patients see multiple doctors before getting diagnosed. It's a disease of waiting and decline.
The announcement mentions "interim data." What does that mean in practical terms?
It means they're not waiting for the full trial to finish. They're presenting early results from the dose-escalation phase—the part where they're figuring out what dose is safe and effective. It's a signal. If something goes badly wrong, you see it early. If it looks promising, you can move faster.
Why would a company partner with Regeneron on this?
Scale and credibility. Regeneron has the manufacturing expertise and commercial reach to take a therapy from the lab to millions of patients. For Intellia, a smaller biotech, that partnership de-risks the bet. If NTLA-2001 works, Regeneron helps ensure it actually reaches the people who need it.
What happens if the interim data is disappointing?
The program doesn't necessarily die, but it slows. They'd need to understand why—was it a safety issue, an efficacy issue, a dosing problem? They'd redesign and try again. But if the data is strong, they move into larger trials. The real test comes when you treat more patients and follow them longer.